← Back to Search

PARP Inhibitor

SBRT + Olaparib and Pembrolizumab + Olaparib for Gastric Cancer

Phase 2
Recruiting
Led By Sunnie S Kim, MD
Research Sponsored by University of Colorado, Denver
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participant must be ≥ 18 years of age
Participant must have at least one radiographically-confirmed index lesion that will not undergo RT and is measurable based on RECIST v1.1
Must not have
Has active autoimmune disease that has required systemic treatment in the past 2 years
Has a known history of Human Immunodeficiency Virus (HIV)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights
No Placebo-Only Group

Summary

This trial tests a treatment for patients with advanced stomach and GEJ cancers who have not responded to previous treatments. It uses a drug called olaparib, precise radiation therapy, and a combination of olaparib and pembrolizumab to damage cancer cells' DNA, target them accurately, and help the immune system fight the cancer.

Who is the study for?
Adults with metastatic gastric or gastroesophageal cancer who've had prior treatment including fluoropyrimidine and platinum drugs. They must be able to swallow pills, have good organ function, and a specific gene mutation related to DNA repair. Pregnant women can't join; men and women must agree to contraception.
What is being tested?
This phase II trial tests if olaparib combined with radiation therapy followed by olaparib plus pembrolizumab improves outcomes in patients with certain genetic mutations after previous treatments for their advanced stomach cancers.
What are the potential side effects?
Possible side effects include fatigue, nausea, skin reactions from radiation, immune-related conditions due to pembrolizumab (like inflammation of organs), blood count changes, and potential allergic reactions to the medications used.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.
Select...
I have at least one tumor that can be measured and hasn't been treated with radiation.
Select...
I have a mutation in a gene linked to DNA repair.
Select...
My stomach cancer is confirmed and can be biopsied.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have an autoimmune disease treated with medication in the last 2 years.
Select...
I have been diagnosed with HIV.
Select...
I have another cancer that is getting worse or was treated in the last 3 years.
Select...
I have had pneumonitis treated with steroids or have it now.
Select...
I have an immune system disorder or have been on high-dose steroids or other immune-weakening medicines recently.
Select...
My stomach and intestines absorb medications normally.
Select...
I have not received a live vaccine in the last 30 days.
Select...
I am currently being treated for an infection.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Objective Response Rate (ORR) of unirradiated tumors
Secondary study objectives
Disease Control Rate (DCR) of Total Cohort and HRD (Homologous Recombination Deficiency) versus HR (Homologous Recombination) proficient.
Duration of Response (DOR) of Total Cohort and HRD (Homologous Recombination Deficiency) versus HR (Homologous Recombination) proficient.
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE v5.0 during concurrent SBRT/olaparib
+2 more

Side effects data

From 2023 Phase 3 trial • 154 Patients • NCT02184195
49%
Nausea
47%
Fatigue
38%
Diarrhoea
29%
Abdominal pain
29%
Anaemia
28%
Constipation
27%
Decreased appetite
27%
Back pain
26%
Vomiting
21%
Arthralgia
19%
Pyrexia
18%
Asthenia
13%
Rash
13%
Nasopharyngitis
11%
Alanine aminotransferase increased
11%
Dyspnoea
10%
Neuropathy peripheral
10%
Cough
10%
Abdominal pain upper
10%
Dyspepsia
10%
Anxiety
10%
Pruritus
9%
Thrombocytopenia
9%
Dizziness
9%
Hyperglycaemia
9%
Aspartate aminotransferase increased
9%
Oedema peripheral
9%
Pain in extremity
9%
Insomnia
9%
Stomatitis
9%
Dry mouth
9%
Headache
9%
Neutropenia
8%
Blood creatinine increased
8%
Weight decreased
7%
Dysgeusia
7%
Blood alkaline phosphatase increased
7%
Neutrophil count decreased
7%
Muscle spasms
7%
Influenza
7%
Influenza like illness
7%
Myalgia
7%
Peripheral sensory neuropathy
7%
Gamma-glutamyltransferase increased
6%
Hypertension
6%
Platelet count decreased
6%
Depression
6%
Lymphopenia
6%
Gastrooesophageal reflux disease
6%
Abdominal distension
5%
Musculoskeletal pain
3%
Flank pain
2%
Cholangitis
2%
Flatulence
2%
Paraesthesia
1%
General physical health deterioration
1%
Bladder papilloma
1%
Pneumonia pneumococcal
1%
Abdominal infection
1%
Bartholinitis
1%
Pneumonia
1%
Cerebrovascular accident
1%
Pneumothorax
1%
Gastric varices haemorrhage
1%
Large intestinal obstruction
1%
Cholecystitis
1%
Anastomotic haemorrhage
1%
Device occlusion
1%
Stent malfunction
1%
Bronchiolitis
1%
Empyema
1%
Syncope
1%
Incisional hernia
1%
Device dislocation
1%
Obstruction gastric
1%
Cardiac failure
1%
Vascular stenosis
1%
Pleural effusion
1%
Incarcerated inguinal hernia
1%
Urinary tract infection
1%
Hypothyroidism
1%
Transient ischaemic attack
1%
Infusion related reaction
1%
Duodenal perforation
1%
Melaena
1%
Bile duct obstruction
1%
Pancreatitis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Olaparib 300 mg Twice Daily (bd)
Placebo

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: HR proficient cohortExperimental Treatment3 Interventions
No identifiable somatic or germline deleterious mutation in DNA Response and Repair pathway
Group II: HR deficient cohortExperimental Treatment3 Interventions
Pre-identified presence of somatic or germline deleterious mutation, as determined by NGS only, in at least one gene critical to DNA repair through homologous recombination, including but not limited to: ARID1A, ATM, ATRX, MRE11A, NBN, PTEN, RAD50/51/51B, BARD1, BLM, BRCA1, BRCA2, BRIP1, FANCA/C/D2/E/F/G/L, PALB2, WRN, CHEK2, CHEK1, BAP1, FAM175A, SLX4, MLL2 or XRCC.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stereotactic Body Radiation Therapy
2012
Completed Phase 2
~790
Pembrolizumab
2017
Completed Phase 3
~2810
Olaparib
2007
Completed Phase 4
~2190

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
PARP inhibitors, such as Olaparib, work by blocking the PARP enzyme, which helps repair DNA damage in cells. By inhibiting this enzyme, cancer cells with already compromised DNA repair mechanisms (like those with BRCA mutations) accumulate DNA damage and eventually die. Pembrolizumab, a PD-1 inhibitor, works by blocking the PD-1 pathway, which cancer cells exploit to evade the immune system. By inhibiting PD-1, Pembrolizumab reactivates immune cells to recognize and attack cancer cells. These treatments are significant for stomach cancer patients as they offer targeted approaches that can improve outcomes, especially in cases where traditional therapies are ineffective.
Quality of life with first-line pembrolizumab for PD-L1-positive advanced gastric/gastroesophageal junction adenocarcinoma: results from the randomised phase III KEYNOTE-062 study.Platinum-based therapy in adenosquamous pancreatic cancer: experience at two institutions.Promising novel therapies for the treatment of endometrial cancer.

Find a Location

Who is running the clinical trial?

Merck Sharp & Dohme LLCIndustry Sponsor
4,001 Previous Clinical Trials
5,184,885 Total Patients Enrolled
University of Colorado, DenverLead Sponsor
1,802 Previous Clinical Trials
2,822,086 Total Patients Enrolled
Sunnie S Kim, MDPrincipal InvestigatorUniversity of Colorado, Denver

Media Library

Olaparib (PARP Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT05379972 — Phase 2
Stomach Cancer Research Study Groups: HR proficient cohort, HR deficient cohort
Stomach Cancer Clinical Trial 2023: Olaparib Highlights & Side Effects. Trial Name: NCT05379972 — Phase 2
Olaparib (PARP Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05379972 — Phase 2
~9 spots leftby Dec 2025